Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DAHLIA: Achievement of Low Level of Disease Activity With a Dose of Corticosteroids Less Than or Equal to 5 mg (LLDAS5): a Real-life Study With Anifrolumab on Patients With Systemic Lupus Erythematosus in Italy

NCT07330245 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07330245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07330245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DAHLIA: Achievement of Low Level of Disease Activity With a Dose of Corticosteroids Less Than or Equal to 5 mg (LLDAS5): a Real-life Study With Anifrolumab on Patients With Systemic Lupus Erythematosus in Italy
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
December 31, 2025
Completion date
September 30, 2028
Enrollment
218 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

lupus erythematosus, systemic